Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting. Improvements in thrombocytopenia and anemia were observed in patients with ...

SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ...

LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk ...

The FDA granted accelerated approval to pacritinib for treatment of adults with myelofibrosis and thrombocytopenia. The approval applies to use of the agent by patients with intermediate- or high-risk ...

Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. Patients with severe ...

Credit: Getty Images. The approval was based on data from the randomized, controlled, phase 3 PERSIST-2 trial. The Food and Drug Administration (FDA) has granted accelerated approval to Vonjo ™ ...

Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational ...

"Myelofibrosis with severe thrombocytopenia, defined as blood platelet counts below 50 × 10 9 /L, has been shown to result in poor survival outcomes coupled with debilitating symptoms. Limited ...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected by CTI BioPharma to be a specialty pharmacy partner for VONJO (pacritinib), which is ...

--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count-- VANCOUVER, BC, Dec. 7, 2020 /PRNewswire/ - Sierra ...